NovoCure Limited

NovoCure Limited

NVCR · Nasdaq

NovoCure Limited (NVCR) is a Medical instruments supplies company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for NovoCure Limited in 2026. The next earnings report is expected on October 22, 2026.

Earnings calendar

Next earnings date

22 Oct 2026

In 64 days

EPS estimate

-0.32

Revenue estimate

176.6M

Past earnings

23 Jul 2026
EPS actual
-0.13 (+60.8%)
estimate -0.33
Revenue actual
183.6M (+6.5%)
estimate 172.4M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
30 Apr 2026
EPS actual
-0.62 (-21.0%)
estimate -0.51
Revenue actual
174.1M (+3.7%)
estimate 167.8M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
26 Feb 2026
EPS actual
-0.22 (+46.5%)
estimate -0.41
Revenue actual
174.4M (0.0%)
estimate 174.4M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

NovoCure beat consensus estimates in its latest earnings report, with EPS of USD -0.13 versus an estimate of USD -0.3315 and revenue of USD 183.58 million, 6.5% above expectations. In the previous report EPS missed expectations while revenue came in ahead of estimates.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Sector
Healthcare
Industry
Medical instruments supplies
Country
Jersey
Exchange
Nasdaq
CEO
Frank Leonard
Employees
1,488
IPO date
01 Oct 2015
ISIN
JE00BYSS4X48
Website
novocure.com

Frequently asked questions

When does NovoCure Limited (NVCR) next report earnings?

NovoCure Limited (NVCR) is scheduled to report earnings on October 22, 2026.

What was NovoCure Limited's most recent earnings date?

NovoCure Limited (NVCR) last reported earnings on July 23, 2026.

Where is NovoCure Limited stock listed?

NovoCure Limited (NVCR) is listed on Nasdaq.